Bibliography
- MORINELLI TA, WEBB JG, JAFFA AA, PRIVITERA PJ, MARGOLIUS HS: A Metabolic Fragment of Bradykinin, Arg-Pro-Pro-Gly-Phe, Protects against the Deleterious Effects of Lipopolysaccharide. Pharmacol Exp. Ther. (2001) 296:71–76.
- SHIMA C, MAJIMA M, KATORI M: A stable metabolite, Arg-Pro-Pro-Gly-Phe, of bradykinin, in the degradation pathway in human plasma. bit. j Pharmacol (1992) 60:111–120.
- MAJIMA M, NISHIYAMA K, IGUCHI Yet al:Determination of bradykinin-(1-5) in inflammatory exudate by a new ELISA as a reliable indicator of bradykinin generation. Inllamm. Res. (1996) 45:416–423.
- MURPHEY LJ, HACHEY DL, OATES JA, MORROW JD, BROWN NJ: Metabolism of bradykinin in viva in human: Identification of BK1-5 as a stable plasma peptide metabolite. I Pharmacol. Exp. Ther. (2000) 294:263–269.
- MURPHEY LJ, HACHEY DL, VAUGHAN DE, BROWN NJ, MORROW JD: Quantification of bk1-5, the stable bradykinin plasma metabolite in humans, by a highly accurate liquid-chromatographic tandem mass spectrometric assay. Anal. Biochem. (2001) 292:87–93.
- HASAN AAK, AMENTA S, SCHMAIERAH: Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of a-thrombin-induced platelet activation. Circulation (1996) 94:517–528.
- HASAN AAK. REBELLO SS, SMITH E: Thrombostatin inhibits induced canine coronary thrombosis. Thromb. Haemostasis (1999) 82:1181–1187.
- MURPHEY LJ, GAINER JV, VAUGHAN DE, BROWN NJ: Angiotension-converting enzyme insertion/deletion polymorphism modulates the human in viva metabolism of bradykinin. Circulation (2000) 102:829–832.